Aclaris Therapeutics (ACRS)
4.41
0.00 (0.00%)
Upcoming Events
Latest Headlines
Aclaris Therapeutis (ACRS) Reiterated at Overweight by Cantor Fitzgerald
September 24, 2026 7:03 AM - StreetInsider
Form SCHEDULE 13G Aclaris Therapeutics, Filed by: Frazier Life Sciences Public Fund, L.P.
September 21, 2026 4:10 PM - SEC Filing
Aclaris Therapeutis (ACRS) Reiterated at Overweight by Cantor Fitzgerald
September 16, 2026 7:53 AM - StreetInsider
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
September 3, 2026 8:00 AM - StreetInsider
Canaccord Starts Aclaris Therapeutis (ACRS) at Buy
September 1, 2026 6:20 AM - StreetInsider
Piper Sandler on Aclaris Therapeutis (ACRS): 'Efficacy Differentiation Could Drive Share Re-Rate'
August 31, 2026 8:52 AM - StreetInsider
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
August 14, 2026 4:44 PM - SEC Filing
Form 8-K Aclaris Therapeutics, For: Aug 06
August 6, 2026 5:15 PM - SEC Filing
Form S-3ASR Aclaris Therapeutics,
August 6, 2026 5:08 PM - SEC Filing
Form 10-Q Aclaris Therapeutics, For: Jun 30
August 6, 2026 4:37 PM - SEC Filing
FDA grants fast track status to Aclaris drug for lichen planus
August 6, 2026 4:36 PM - StreetInsider
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
August 6, 2026 4:35 PM - StreetInsider
Form 8-K Aclaris Therapeutics, For: Aug 06
August 6, 2026 7:15 AM - SEC Filing
Aclaris Therapeutics (ACRS) Tops Q2 EPS by 1c
August 6, 2026 7:05 AM - StreetInsider
Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
August 6, 2026 6:59 AM - StreetInsider
Form 4 Aclaris Therapeutics, For: Aug 01 Filed by: Kolbeck Roland Wilhelm
August 4, 2026 5:03 PM - SEC Filing
Full Article List
